Multi-omic profiling reveals metabolic vulnerabilities in enzalutamide resistant prostate cancer.
8 affiliations
- 1Department of Anatomy and Physiology, The University of Melbourne, Melbourne, VIC, Australia.
- 2Department of Medicine, National University of Singapore, Singapore, Singapore.
- 3Cardiovascular Metabolic Disease Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- 4Department of Physiology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia.
- 5Cancer Immunology Program, Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
- 6Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
- 7Cabrini Institute, Cabrini Health, Melbourne, VIC, Australia.
- 8Department of Anatomy and Physiology, The University of Melbourne, Melbourne, VIC, Australia. [email protected].
Abstract
Resistance to the androgen receptor inhibitor enzalutamide (ENZ) is a major barrier to durable control of advanced prostate cancer. Given the central role of metabolic reprogramming in tumour survival under therapeutic stress, we investigated whether ENZ resistance is associated with adaptive metabolic rewiring that promotes stress tolerance and evasion of cell death. Multi-omic profiling of ENZ-sensitive (C4-2B and V16D) and ENZ-resistant (MR49F) cells revealed extensive metabolic reprogramming, with lipid metabolism emerging as a dominant axis. ENZ-resistant cells displayed depletion of long-chain polyunsaturated fatty acids (PUFAs) and increased resistance to lipid peroxidation and ferroptosis. Restoring PUFA availability or activating lipid regulatory pathways via treatment with a liver X receptor (LXR) agonist re-sensitised resistant cells to ferroptotic cell death. In parallel, nitrogen metabolism was altered in ENZ-resistant cells, including increased carbamoyl phosphate synthetase 1 (CPS1) and resistance to ammonium exposure. Treatment with the CPS1 inhibitor H3B-120 reduced proliferation of MR49F cells and increased their sensitivity to ammonium stress. Together, these findings identify coordinated lipid and nitrogen remodelling as targetable metabolic adaptations that support resistance to cellular stress and death in ENZ-resistant prostate cancer cells.
Related
- Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database
- Tumor-targeted nanobubbles delivering PFP/siFGFR1 for US imaging and overcoming enzalutamide-resistant in prostate cancer
- Skin‐Related Adverse Events in Patients Treated With Apalutamide Versus Enzalutamide for Prostate Cancer: A Japanese Real‐World Database Study (A Retrospective Cohort Study)
- Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)
- IGF1R Induces ROS Formation in Mitochondria via MICU1 Leads to the Enzalutamide Resistance in Prostate Cancer
BibTeX
@article{lee2026multiomic,
title = {{Multi-omic profiling reveals metabolic vulnerabilities in enzalutamide resistant prostate cancer.}},
author = {Olivia Lee and Gio Fidelito and Qing Zhao and Bingshou Liu and Hyungwon Choi and Renea A Taylor and Matthew J Watt},
journal = {Cell death discovery},
year = {2026},
month = sep,
doi = {10.1038/s41420-026-03332-3},
url = {https://europepmc.org/article/MED/42957627},
note = {CC BY},
}
RIS
TY - JOUR
TI - Multi-omic profiling reveals metabolic vulnerabilities in enzalutamide resistant prostate cancer.
AU - Olivia Lee
AU - Gio Fidelito
AU - Qing Zhao
AU - Bingshou Liu
AU - Hyungwon Choi
AU - Renea A Taylor
AU - Matthew J Watt
PY - 2026
DA - 2026/09/09
JO - Cell death discovery
DO - 10.1038/s41420-026-03332-3
UR - https://europepmc.org/article/MED/42957627
AB - Resistance to the androgen receptor inhibitor enzalutamide (ENZ) is a major barrier to durable control of advanced prostate cancer. Given the central role of metabolic reprogramming in tumour survival under therapeutic stress, we investigated whether ENZ resistance is associated with adaptive metabolic rewiring that promotes stress tolerance and evasion of cell death. Multi-omic profiling of ENZ-sensitive (C4-2B and V16D) and ENZ-resistant (MR49F) cells revealed extensive metabolic reprogramming, with lipid metabolism emerging as a dominant axis. ENZ-resistant cells displayed depletion of long-chain polyunsaturated fatty acids (PUFAs) and increased resistance to lipid peroxidation and ferroptosis. Restoring PUFA availability or activating lipid regulatory pathways via treatment with a liver X receptor (LXR) agonist re-sensitised resistant cells to ferroptotic cell death. In parallel, nitrogen metabolism was altered in ENZ-resistant cells, including increased carbamoyl phosphate synthetase 1 (CPS1) and resistance to ammonium exposure. Treatment with the CPS1 inhibitor H3B-120 reduced proliferation of MR49F cells and increased their sensitivity to ammonium stress. Together, these findings identify coordinated lipid and nitrogen remodelling as targetable metabolic adaptations that support resistance to cellular stress and death in ENZ-resistant prostate cancer cells.
SN - 2058-7716
ER -